StockData
Regencell Bioscience Holdings Ltd logo

Regencell Bioscience Holdings Ltd (RGC) stock

RGCNasdaqMedicinal Chemicals & Botanical Products
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 7, 2026Score 5/30
$4.55−0.17 (-3.60%)

Close on Nov 17, 2026Market cap $2.26BP/E –Yield –

Regencell Bioscience cash

Cash and short-term investments held at the end of each period.

Regencell Bioscience's cash was $14.19M at Jun 30, 2026. For fiscal 2026 it was $14.19M, up 189.8% from the year before. The highest annual figure on record is $16.42M in fiscal 2022.

Annual cash

PeriodPeriod endValueChange
FY2026Jun 30, 2026$14.19M+189.8%
FY2025Jun 30, 2025$4.90M-38.5%
FY2024Jun 30, 2024$7.96M-31.2%
FY2023Jun 30, 2023$11.56M-29.6%
FY2022Jun 30, 2022$16.42M+27532.0%
FY2021Jun 30, 2021$59.41K-84.6%
FY2020Jun 30, 2020$386.98K+59.0%
FY2019Jun 30, 2019$243.31K+58.7%
FY2018Jun 30, 2018$153.30K–

Quarterly cash

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jun 30, 2026$14.19M+78.3%
Q2 FY2026CQ4 2025Dec 31, 2025$2.36M-79.6%
Q4 FY2025CQ2 2025Jun 30, 2025$4.90M-70.2%
Q2 FY2025CQ4 2024Dec 31, 2024$1.58M+2553.0%
Q4 FY2024CQ2 2024Jun 30, 2024$7.96M+1957.3%
Q4 FY2023CQ2 2023Jun 30, 2023$11.56M+4653.2%
Q4 FY2022CQ2 2022Jun 30, 2022$16.42M+10608.9%
Q4 FY2021CQ2 2021Jun 30, 2021$59.41K–
Q4 FY2020CQ2 2020Jun 30, 2020$386.98K–
Q4 FY2019CQ2 2019Jun 30, 2019$243.31K–
Q4 FY2018CQ2 2018Jun 30, 2018$153.30K–

More Regencell Bioscience figures

See a number that looks wrong?